Citius Oncology
CTOR
23 hedge funds and large institutions have $69M invested in Citius Oncology in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
160% more capital inflows, than outflows
Capital inflows: $9.9M | Capital outflows: $3.81M
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5.37% more ownership
Funds ownership: 65.14% → 70.51% (+5.4%)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$2.99M |
| 2 |
Yakira Capital Management
Westport,
Connecticut
|
+$2.45M |
| 3 |
HGC Investment Management
Toronto,
Ontario, Canada
|
+$2.07M |
| 4 |
Cowen and Company
New York
|
+$466K |
| 5 |
Mizuho Securities USA
New York
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kepos Capital
New York
|
-$2.42M |
| 2 |
Shaolin Capital Management
Miami,
Florida
|
-$654K |
| 3 |
Karpus Investment Management
Pittsford,
New York
|
-$392K |
| 4 |
CVI Holdings
Wilmington,
Delaware
|
-$156K |
| 5 |
Virtu Financial
New York
|
-$130K |
CTOR Hedge Fund Activity: Q4 2023 in Review
23 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q4 2023, worth a combined $69M — up 10% from $62.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CTOR positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was W.R. Berkley Corp, adding an estimated $2.99M. The largest seller was Kepos Capital, exiting entirely with an estimated $2.42M sold.
- 23 institutional investors held Citius Oncology (CTOR) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $69M of Citius Oncology stock for Q4 2023, up 10% quarter-over-quarter.
- 3 funds opened new Citius Oncology positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Citius Oncology buyer in Q4 2023 was W.R. Berkley Corp, an estimated $2.99M added.
- The largest Citius Oncology seller in Q4 2023 was Kepos Capital, an estimated $2.42M sold.
Based on aggregated 13F filings for Q4 2023.